What does ESGLD stand for?

an update on the low dose study OGT 918-003, originally presented in poster form at the European Study Group on Lysosomal Diseases (ESGLD, Woudschoten, the Netherlands, September 2001) with the full paper being published in Blood Cells, Molecules, and Diseases 28 (2) March 2002.

Highlights Vevesca (OGT 918): -- Completion of submission to US and EU regulatory authorities for Vevesca (OGT 918) for the treatment of type 1 Gaucher disease; -- Exclusive agreement signed with Teva for the marketing of Vevesca (OGT 918) in Israel; -- Presented clinical results at the European Study Group on Lysosomal Diseases meeting in September 2001 -- 24 month follow up data (study 001 ext) and dose comparison study (003) -- 12 month dataset on dose comparison study subsequently published in the journal Blood Cells, Molecules and Diseases in March 2002; -- Following the year end, announcement of intention to expand OGT 918 clinical trials to Niemann-Pick Type C disease, Neuronopathic (Type 3) Gaucher disease and Late Onset GM2 Gangliosidosis.

Further results on follow-up and dose comparison studies on Vevesca (OGT 918) presented at the European Study Group on Lysosomal Diseases on 22 September (see today's announcement).